Company news

Spyre Therapeutics, Inc. news in 2021

Spyre Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency

December 5, 2021

Aeglea BioTherapeutics to Host Conference Call to Report Phase 3 Topline Results of Pegzilarginase in Patients with Arginase 1 Deficiency

December 4, 2021

Aeglea BioTherapeutics Appoints Hunter C. Smith to Board of Directors

November 15, 2021

Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights

November 3, 2021

Aeglea BioTherapeutics Announces Presentation of Seven Abstracts at ICIEM 2021 Including Oral Presentation of PEACE Study Baseline Characteristics

November 3, 2021

Aeglea BioTherapeutics to Participate in Multiple Conferences in September 2021

August 31, 2021

Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights

August 4, 2021

Aeglea BioTherapeutics Appoints Jim Kastenmayer as General Counsel

July 14, 2021

Aeglea BioTherapeutics Announces Publication of 20 Week Data from Phase 1/2 and Open-Label Extension Studies of Pegzilarginase for the Treatment of Arginase 1 Deficiency in the Journal of Inherited Metabolic Disease

July 13, 2021

Aeglea BioTherapeutics Appoints Jonathan D. Alspaugh as Chief Financial Officer

July 7, 2021

Aeglea BioTherapeutics Doses First Patient in a Phase 1/2 Clinical Trial of AGLE-177, a Potential First-in-Class Treatment for Homocystinuria

June 23, 2021

Aeglea BioTherapeutics Appoints Marcio Souza to Board of Directors

June 21, 2021

Aeglea BioTherapeutics Reports First Quarter 2021 Financial Results and Corporate Highlights

May 9, 2021

Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency

May 5, 2021

Aeglea BioTherapeutics Completes Patient Randomization for PEACE, its Pivotal Phase 3 Clinical Trial of Pegzilarginase for the Treatment of Arginase 1 Deficiency

May 2, 2021

Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021

March 31, 2021

Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East

March 21, 2021

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights

March 17, 2021

Aeglea BioTherapeutics Appoints Sara Brownstein to Board of Directors

February 23, 2021

Aeglea BioTherapeutics Announces Transition of Chief Financial Officer

February 2, 2021

Aeglea BioTherapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

January 3, 2021

Decks in 2021